Regeneron’s Eylea Combination Misses Phase II Endpoints in Wet AMD

October 6, 2016

A Phase II trial evaluating the addition of rinucumab to Eylea (aflibercept) treatment failed to meet the primary endpoint of a Phase II trial in patients with wet age-related macular degeneration. Eylea and rinucumab, an anti-platelet-derived growth factor receptor beta, were both developed by Regeneron Pharmaceuticals.

The combination therapy did not demonstrate an improvement in best corrected visual acuity compared to intravitreal Eylea injection monotherapy after 12 weeks: patients receiving combination showed a 5.8 letter improvement in BCVA, and patients treated with Eylea alone showed a 7.5 letter improvement. Eylea results were consistent with those seen in previous Phase III studies.

The ongoing multiple-dose study has enrolled approximately 500 patients. Data will be evaluated at 28 weeks and 52 weeks, when the study is completed.

View today's stories